European Atherosclerosis Society (EAS) & Congress

European Atherosclerosis Society (EAS) & Congress For more than 50 years the Society’s expertise has been used to teach clinicians how to manage lipid disorders and how to prevent atherosclerosis.

The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”. By offering to our members access to educational materials, and opportunities to take part in Congress and courses, and by providing a forum in which new developments can be discussed, EAS co

ntributes to the development of knowledge in the field, and ultimately to the improved treatment of persons with cardiovascular disease and lipid disorders. In recent years the Society has made a particular effort to recruit young scientists and clinicians also from other related disciplines. What we do
The European Atherosclerosis Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis. EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. Through a regular series of Featured Commentaries EAS puts into perspective topical issues of relevance to our members. The Society organizes an annual Congress for approximately 2000 delegates, and runs a programme of Advanced Courses for both basic scientists and clinicians. EAS Academy is the Society's online e-Learning resource, containing a range of educational material and self-teaching programmes.

Day 2: A session or speaker that you still remember...Was there a presentation, discussion, or conversation at a past EA...
11/05/2026

Day 2: A session or speaker that you still remember...

Was there a presentation, discussion, or conversation at a past EAS Congress that stayed with you long after the session ended? Perhaps it was a speaker who challenged your perspective, a research finding that influenced your work, or a discussion that led to a valuable collaboration.

Share your story with us using and tell us which EAS Congress moment left a lasting impression on you.

🔗 https://bit.ly/4bWGy2z

Day 1 of the challenge!We’re starting with a question for the EAS community: When and where did you attend your first ...
10/05/2026

Day 1 of the challenge!

We’re starting with a question for the EAS community: When and where did you attend your first EAS Congress?

Was it your first opportunity to connect with the EAS community, present your research, meet collaborators, or learn from experts in the field? Or will Athens 2026 be your very first EAS Congress experience?

Make sure to include and post a photo from your first EAS Congress if you have one. We’d love to see the moments and memories that brought you to the EAS community.

🔗 https://bit.ly/4bWGy2z

08/05/2026

Several clear outcomes from the Perfecto FH Closing Event will now be delivered to help drive meaningful and lasting change

What defines the structure of “bad” lipoproteins - and why does it matter for cardiovascular risk? 🔬 🥼 At , Alan Remale...
07/05/2026

What defines the structure of “bad” lipoproteins - and why does it matter for cardiovascular risk? 🔬 🥼

At , Alan Remaley (USA) will explore this question in Plenary 1: Lipids and Lipoproteins Beyond the Liver, focusing on the structure of atherogenic lipoproteins and their role in disease.

Dr. Remaley leads the Lipoprotein Metabolism Laboratory at NHLBI and has authored over 500 publications in the field, translating research into new diagnostic and therapeutic approaches.

🔗Find out more:  https://eas-congress.com/2026/programme/scientific-programme/

What does it take to build a career at the intersection of clinical care, research, and global collaboration? In this ep...
06/05/2026

What does it take to build a career at the intersection of clinical care, research, and global collaboration? In this episode of AtheroTalk, we speak with Prof. Pablo Corral from Argentina, who brings a grounded and insightful perspective on lipid disorders, cardiovascular prevention, and the evolving role of large-scale clinical trials.

From tackling familial hypercholesterolemia to addressing residual risk, he shares both the realities and possibilities of advancing care in Latin America. Along the way, he reflects on mentorship, career choices, and what truly sustains long-term motivation, captured in one simple idea: “Find something you are truly passionate about.”

A thoughtful conversation for anyone navigating science, medicine, and purpose.

🎧 Spotify: https://eas.to/ATHTalkE32S
🎧 Apple Podcasts: https://eas.to/ATHTalkE32A
🎧 Youtube: https://eas.to/ATHTalkE32Y

05/05/2026

Magdalena Daccord notes that the Perfecto FH Closing Event brought together a highly committed group of stakeholders from diverse sectors, and now we need to ensure that tangible outcomes emerge from the meeting.

How does exercise influence cardiovascular disease beyond traditional risk factors? 🔬 At , Hendrik Sager, Germany, will...
05/05/2026

How does exercise influence cardiovascular disease beyond traditional risk factors? 🔬

At , Hendrik Sager, Germany, will explore this in Exercise and Cardiovascular Disease during Plenary 1: Lipids and Lipoproteins Beyond the Liver.

Prof. Sager’s research focuses on the inflammatory component of cardiovascular disease, particularly the role of monocytes and macrophages in atherosclerosis and post-infarction healing.

🔗 Find out more: https://eas-congress.com/2026/programme/plenary-programme/

Reminder: As three members of the ELC Organizing Committee will complete their terms at the end of 2026, we are inviting...
04/05/2026

Reminder: As three members of the ELC Organizing Committee will complete their terms at the end of 2026, we are inviting ELC members to nominate candidates for these upcoming positions.

Joining the Organizing Committee offers the opportunity to actively contribute to the planning and success of the ELC Annual Scientific Meeting through:
🟥 Setting the principles for scientific abstract evaluation
🟥 Reviewing and selecting submitted abstracts
🟥 Assisting with fundraising activities

Nominations are open until 10 May. More information and nomination submission: https://eas.to/ELC2026Nom

Today, on HoFH Awareness Day, we raise awareness of Homozygous Familial Hypercholesterolaemia (HoFH) and stand with pati...
04/05/2026

Today, on HoFH Awareness Day, we raise awareness of Homozygous Familial Hypercholesterolaemia (HoFH) and stand with patients and families affected by this severe inherited condition.

By increasing understanding, promoting early detection, and advocating for timely treatment, we can help improve lives and drive change worldwide: https://eas.to/HoFHD2026

03/05/2026

The aim is to harmonize lipid clinics worldwide and help them become champions of optimal patient care.

One of the hottest debates in cardiovascular prevention is here. Should we be screening the families of patients with el...
02/05/2026

One of the hottest debates in cardiovascular prevention is here. Should we be screening the families of patients with elevated Lipoprotein(a) - or are we moving faster than the evidence allows?

Join Dr Jaimini Cegla, leading lipidology specialist and NHS England advisor on CVD prevention, as she tackles this timely question in a compelling Featured Open Lecture.

With insights from clinical practice, laboratory science, and academic research, Dr Cegla delivers a balanced, evidence-based discussion on the cascade screening for elevated Lp(a).

▶️ Watch the lecture now: https://eas.to/OpenMay26

Adress

Första Långgatan 4A
Gothenburg
41303

Webbplats

Aviseringar

Var den första att veta och låt oss skicka ett mail när European Atherosclerosis Society (EAS) & Congress postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Praktiken

Skicka ett meddelande till European Atherosclerosis Society (EAS) & Congress:

Genvägar

Dela